Pneumococcal Vaccines Market : Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

The report on the global pneumococcal vaccines market provides qualitative and quantitative analysis for the period from 2021-2030. The global pneumococcal vaccines market was valued at USD 7.82 billion in 2022 and is expected to reach USD 11.51 billion in 2030, with a CAGR of 4.20% during the forecast period 2023-2030. The study on pneumococcal vaccines market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

Pneumococcal vaccines are immunizations designed to protect against infections caused by Streptococcus pneumoniae bacteria. These vaccines work by stimulating the immune system to produce antibodies that can combat the bacteria, thereby reducing the risk of pneumococcal diseases such as pneumonia, meningitis, and sepsis. There are two main types of pneumococcal vaccines in use such as the Pneumococcal Conjugate Vaccines (PCV 10/PCV13) and the Pneumococcal Polysaccharide Vaccine (PPSV23). PCV13 is recommended for children aged 6 to 18 and adults with underlying health conditions, while PPSV23 is typically administered to individuals over 65 and, in specific instances, to infants aged over two. The World Health Organization (WHO) advocates the inclusion of pneumococcal conjugate vaccines in routine immunization schedules for children. By immunizing infants and young children, these vaccines help reduce morbidity and mortality rates associated with severe pneumococcal infections. This not only safeguards the health and well-being of the youngest population but also lessens the burden on healthcare systems by diminishing hospitalizations and treatment costs, ultimately contributing to improved public health outcomes.

The increasing incidence of pneumococcal diseases, including pneumonia, sepsis, and meningitis, is a significant catalyst for the expansion of the pneumococcal vaccines market. These vaccines play a crucial role in preventing and reducing the burden of these life-threatening infections, driving their demand and market growth. Additionally, government and private sector initiatives aimed at broadening vaccination programs and extending coverage to previously underserved populations are fueling the growth of the pneumococcal vaccines market. These concerted efforts are increasing accessibility and raising awareness, ultimately leading to a larger market and greater immunization rates against pneumococcal diseases. However, the pneumococcal vaccines market faces hindrances due to the substantial manufacturing expenses involved. The high costs incurred in research, development, and production limit affordability and accessibility, impeding the market's growth and hampering efforts to combat pneumococcal diseases on a broader scale. Although, the pneumococcal vaccines market is witnessing growth opportunities due to innovative vaccine research techniques and rising demand in developing regions. These advancements enhance vaccine efficacy and safety, while the increasing demand in less-developed areas opens new markets, addressing unmet healthcare needs and driving market expansion.

North America holds the maximum market share in the pneumococcal vaccines market. Increased investment in the R&D sector and favorable government initiatives are the major factors responsible for the growth of the market in the North America region. Pharmaceutical companies in North America actively develop and distribute pneumococcal vaccines. Additionally, stringent regulatory guidelines contribute to the region's leading market share, with established players such as Pfizer and Merck maintaining a strong presence. Moreover, the fastest-growing region for pneumococcal vaccines is Asia-Pacific. This growth is driven by several factors, including increasing awareness of vaccine-preventable diseases, a growing population, and expanding healthcare access in emerging economies. Furthermore, the rising middle class and greater healthcare expenditure contribute to the growing demand for pneumococcal vaccines in this region. As a result, Asia-Pacific is witnessing a rapid increase in market share, with several vaccine manufacturers investing in the region to tap into this significant growth potential.

Report Findings

1) Drivers

• Rising prevalence of pneumococcal diseases such as pneumonia, sepsis, and meningitis are a major driving factor for the growth of pneumococcal vaccines market.
• Government and private sector efforts to expand vaccination initiatives and reach new target demographics are driving growth in the pneumococcal vaccines market.

2) Restraints

• High cost associated with the manufacturing of vaccines is restraining the growth of pneumococcal vaccines market.

3) Opportunities

• Advanced vaccine research methods and increasing demand in developing regions are creating growth opportunities in the pneumococcal vaccine market.

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents.

The primary respondents approached include:

1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segments Covered

The global pneumococcal vaccines market is segmented on the basis of product type, and distribution channel.

The Global Pneumococcal Vaccines Market by Product Type

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

The Global Pneumococcal Vaccines Market by Distribution Channel

• Clinics
• Hospitals
• Non-governmental Organizations
• Government Authorities

Company Profiles

The companies covered in the report include:

• GSK plc
• Pfizer Inc.
• Cochin Shipyard Limited
• Serum Institute of India Pvt. Ltd.
• Merck & Co., Inc.
• Beijing Minhai Biotechnology Co., Ltd.
• Astellas Pharma Inc.
• Walvax Biotechnology Co
• Panacea Biotec
• SK bioscience

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the pneumococcal vaccines market.

2. Complete coverage of all the segments in the pneumococcal vaccines market to analyze the trends, developments in the global market and forecast of market size up to 2030.

3. Comprehensive analysis of the companies operating in the global pneumococcal vaccines market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.